Lupus Nephritis Composite Outcome Measure Recommended For Approval

Lupus nephritis surrogate endpoints, including reduction in double-stranded DNA antibodies, are insufficiently developed to stand alone as primary outcomes for studies, FDA's Arthritis Advisory Committee concluded at its meeting Sept. 29